Lexeo Q2 net loss $21.2M; positive interim gene therapy data in FA cardiomyopathy

Lexeo Therapeutics, Inc.

2024-Q2 EPS reported -$1.41

Net loss of $21.2M ($0.64 per share) vs $13.4M ($8.30) year ago; R&D $16.6M, G&A $7.0M.
Cash $175M expected to fund operations into 2027.
LX2006 for FA cardiomyopathy showed no treatment-related serious adverse events; FDA engagement for registrational study surrogate endpoints initiated.
Phase 1/2 trial for LX2020 (PKP2-ACM) recruiting; Cohort 1 data update on track for 2H 2024.
Tim Van Hauwermeiren (co-founder/CEO argenx) appointed to Board in July 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.